-
公开(公告)号：US08404274B2
公开(公告)日：2013-03-26
申请号：US10559373
申请日：2004-06-04
CPC分类号： A61J1/2093 , A61J1/10 , A61J1/2024
摘要： There is provided an aseptic combination preparation to be mixed at the time of use, characterized in that the same medicinal ingredients are divided and preserved in two or more chambers. The aseptic combination preparations according to the present invention are a mixing type at the time of their use and are useful as infusions, various dialysis fluids, intraocular perfusion/washing solutions, coronary perfusion solutions, myocardial protective solutions, peritoneal lavage solutions, solutions for organ preservations, etc., which can eliminate adverse effects caused by medical error on a living body.
摘要翻译： 提供在使用时混合的无菌组合制剂，其特征在于将相同的药物成分分成并保存在两个或更多个室中。 根据本发明的无菌组合制剂是其使用时的混合型，可用作输注，各种透析液，眼内灌注/洗涤溶液，冠状动脉灌注溶液，心肌保护溶液，腹膜灌洗溶液，器官溶液 保护等，可以消除生物体的医疗误差引起的不良反应。
-
公开(公告)号：US20060154873A1
公开(公告)日：2006-07-13
申请号：US10559373
申请日：2004-06-04
CPC分类号： A61J1/2093 , A61J1/10 , A61J1/2024
摘要： There is provided an aseptic combination preparation to be mixed at the time of use, characterized in that the same medicinal ingredients are divided and preserved in two or more chambers. The aseptic combination preparations according to the present invention are a mixing type at the time of their use and are useful as infusions, various dialysis fluids, intraocular perfusion/washing solutions, coronary perfusion solutions, myocardial protective solutions, peritoneal lavage solutions, solutions for organ preservations, etc., which can eliminate adverse effects caused by medical error on a living body.
-
公开(公告)号：US09446184B2
公开(公告)日：2016-09-20
申请号：US13990018
申请日：2011-11-28
申请人： Seiji Tani , Yasuhiro Mitsumoto
发明人： Seiji Tani , Yasuhiro Mitsumoto
IPC分类号： A61M5/14 , A61K31/07 , A61K31/122 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/51 , A61K31/525 , A61K31/593 , A61K31/714 , A61K33/14 , A61K45/06 , A61J1/20 , A61K9/00
CPC分类号： A61M5/1407 , A23L33/115 , A23L33/125 , A23L33/15 , A23L33/175 , A23V2002/00 , A61J1/2093 , A61K9/0029 , A61K31/07 , A61K31/122 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/4172 , A61K31/4415 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/593 , A61K31/675 , A61K31/685 , A61K31/7004 , A61K31/714 , A61K33/14 , A61K36/48 , A61K45/06 , A61K2300/00
摘要： An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.
摘要翻译： 本发明的目的是提供一种输液制剂，其中在储存期间不会发生氨基酸和还原糖之间的美拉德反应，并且脂肪乳剂中的脂肪颗粒的尺寸在储存期间不增加，并且其中各种 维生素类型可以以稳定的方式并入，尽管它是两室输注制剂。 此外，即使仅输入（输注制剂）的一种，患者也不可能发生高钾血症，血管性疼痛或静脉炎。 本发明提供一种包含两个腔室的输注制剂，所述两个腔室由能够可通信地打开的隔板分开，其中第一腔室包含含有糖和脂肪乳剂的第一室输液器，第二腔室包含含有氨基 酸和电解质，第一室输液基本上不含钾，相对渗透压为2.0〜3.0，第二室输液的钾浓度为40mEq / L以下，相对渗透压为2.5 至3.5，并且第一和第二室输液的混合物在可通气地打开隔板时测量的钾浓度为16mEq / L或更高。
-
4.发明申请公开(公告)号：US20060211631A1
公开(公告)日：2006-09-21
申请号：US10556772
申请日：2004-05-14
IPC分类号： A61K31/70 , A61K31/4172 , A61K31/405 , A61K31/401 , A61K31/198 , A61K31/51
CPC分类号： A61K31/51 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/7004 , A61K33/14 , A61K2300/00
摘要： The infusion preparation for peripheral parenteral administration comprises an infusion (A) containing glucose with 80 to 200 g/L concentration, and an infusion (B) containing amino acid with 50 to 150 g/L concentration. The infusion (A) and the infusion (B) are separately put into a vessel that is divided with an openable partition means. The infusion (A) does not contain sulfite, has titratable acidity of 1 or less, contains vitamin B1 and is adjusted to pH 3 to 5. The infusion (B) is adjusted to pH 6.5 to 8. After mixing the both infusions, the mixture has pH 6 to 7.5 and titratable acidity of 5 to 10.
摘要翻译： 用于外周肠胃外给药的输注制剂包括含有80-200g / L浓度的葡萄糖的输注（A）和含有50-150g / L浓度的氨基酸的输注（B）。 输液（A）和输液（B）分别放入用可打开的分隔装置分开的容器中。 输液（A）不含亚硫酸盐，滴定酸度为1以下，含有维生素B1，调节至pH3〜5。输液（B）调节至pH6.5〜8。混合两次后， 混合物的pH为6〜7.5，滴定酸度为5〜10。
-
公开(公告)号：US20130313261A1
公开(公告)日：2013-11-28
申请号：US13990018
申请日：2011-11-28
申请人： Seiji Tani , Yasuhiro Mitsumoto
发明人： Seiji Tani , Yasuhiro Mitsumoto
IPC分类号： A61J1/20
CPC分类号： A61M5/1407 , A23L33/115 , A23L33/125 , A23L33/15 , A23L33/175 , A23V2002/00 , A61J1/2093 , A61K9/0029 , A61K31/07 , A61K31/122 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/4172 , A61K31/4415 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/593 , A61K31/675 , A61K31/685 , A61K31/7004 , A61K31/714 , A61K33/14 , A61K36/48 , A61K45/06 , A61K2300/00
摘要： An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.
摘要翻译： 本发明的目的是提供一种输液制剂，其中在储存期间不会发生氨基酸和还原糖之间的美拉德反应，并且脂肪乳剂中的脂肪颗粒的尺寸在储存期间不增加，并且其中各种 维生素类型可以以稳定的方式并入，尽管它是两室输注制剂。 此外，即使仅输入（输注制剂）的一种，患者也不可能发生高钾血症，血管性疼痛或静脉炎。 本发明提供一种包含两个腔室的输注制剂，所述两个腔室由能够可通信地打开的隔板分开，其中第一腔室包含含有糖和脂肪乳剂的第一室输液器，第二腔室包含含有氨基 酸和电解质，第一室输液基本上不含钾，相对渗透压为2.0〜3.0，第二室输液的钾浓度为40mEq / L以下，相对渗透压为2.5 至3.5，并且第一和第二室输液的混合物在可通气地打开隔板时测量的钾浓度为16mEq / L或更高。
-
公开(公告)号：US08273717B2
公开(公告)日：2012-09-25
申请号：US10542660
申请日：2004-02-05
IPC分类号： A61K31/7004 , A61K31/70 , A61K31/195
CPC分类号： A61K31/198
摘要： An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.
摘要翻译： 用于围手术期血糖升高的抑制剂，其特征在于含有支链氨基酸，可以在体内转化成支链氨基酸的化合物或从支链氨基酸转移氨基的化合物。 这种围手术期血糖升高抑制剂作为对人体生物有安全的药物有用，抑制由麻醉，手术等引起的血糖水平的异常升高，能够适当地控制血糖 围手术期患者。
-
7.发明授权Heater unit and thermal fusion apparatus for synthetic resin members and thermal fusion method for synthetic resin members 失效用于合成树脂构件的加热单元和热融合装置以及用于合成树脂构件的热融合方法公开(公告)号：US07984739B2
公开(公告)日：2011-07-26
申请号：US11658430
申请日：2005-07-26
IPC分类号： B29C65/32
CPC分类号： B29C65/305 , A61M39/12 , A61M39/146 , A61M2205/3653 , B29C65/18 , B29C65/32 , B29C66/1122 , B29C66/534 , B29C66/5344 , B29C66/612 , B29C66/71 , B29C66/712 , B29C66/73152 , B29C66/80 , B29C66/81811 , B29C66/8432 , B29C66/857 , B29K2101/12 , B29K2995/007 , B29L2023/007 , B29L2031/7544 , B29K2021/003 , B29K2023/00 , B29K2027/06 , B29K2069/00
摘要： It is intended to provide a method of producing thermally fused synthetic resin members for medical use which makes it possible that, in the case of thermally fusing synthetic resin members for medical use, for example, a relatively soft thermoplastic tube constituting an AVF needle with another part being harder than the tube such as a needle base (hub) of a wing needle, or a part provided with a fitting connector being harder than the tube (for example, a blood circuit, an extension tube, an infusion set or the like), the connecting parts of the thermoplastic tube member and the other member harder than the thermoplastic tube member can be quickly and uniformly thermal-fused and the production process can be automatically and continuously performed while keeping a high productivity; and a production apparatus therefor.
摘要翻译： 本发明提供一种生产用于医疗用途的热熔合成树脂构件的方法，其使得在将医疗用合成树脂构件热熔合的情况下，例如，可以将构成AVF针的相对软的热塑性管与另一种 部分比诸如针针的针座（毂）或具有比管更硬的配件连接器的部分（例如，血液回路，延长管，输液器等等）比管更硬 ），热塑性管构件的连接部分和比热塑性管构件更硬的另一构件可以快速且均匀地热熔融，并且可以在保持高生产率的同时自动连续地执行制造过程; 及其制造装置。
-
公开(公告)号：US20060116426A1
公开(公告)日：2006-06-01
申请号：US10542660
申请日：2004-02-05
IPC分类号： A61K31/198
CPC分类号： A61K31/198
摘要： An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc., and enables proper blood sugar control, when administered to a perioperative patient.
摘要翻译： 用于围手术期血糖升高的抑制剂，其特征在于含有支链氨基酸，可以在体内转化成支链氨基酸的化合物或从支链氨基酸转移氨基的化合物。 这种围手术期血糖升高抑制剂作为对人体生物有安全的药物有用，抑制由麻醉，手术等引起的血糖水平的异常升高，能够适当地控制血糖 围手术期患者。
-
9.发明申请Heater Unit and Thermal Fusion Apparatus For Synthetic Resin Members and Thermal Fusion Method For Synthetic Resin Members 失效合成树脂部件的加热单元和热融合装置以及合成树脂部件的热融合方法公开(公告)号：US20090038756A1
公开(公告)日：2009-02-12
申请号：US11658430
申请日：2005-07-26
IPC分类号： B29C65/18
CPC分类号： B29C65/305 , A61M39/12 , A61M39/146 , A61M2205/3653 , B29C65/18 , B29C65/32 , B29C66/1122 , B29C66/534 , B29C66/5344 , B29C66/612 , B29C66/71 , B29C66/712 , B29C66/73152 , B29C66/80 , B29C66/81811 , B29C66/8432 , B29C66/857 , B29K2101/12 , B29K2995/007 , B29L2023/007 , B29L2031/7544 , B29K2021/003 , B29K2023/00 , B29K2027/06 , B29K2069/00
摘要： It is intended to provide a method of producing thermally fused synthetic resin members for medical use which makes it possible that, in the case of thermally fusing synthetic resin members for medical use, for example, a relatively soft thermoplastic tube constituting an AVF needle with another part being harder than the tube such as a needle base (hub) of a wing needle, or a part provided with a fitting connector being harder than the tube (for example, a blood circuit, an extension tube, an infusion set or the like), the connecting parts of the thermoplastic tube member and the other member harder than the thermoplastic tube member can be quickly and uniformly thermal-fused and the production process can be automatically and continuously performed while keeping a high productivity; and a production apparatus therefor.
摘要翻译： 本发明提供一种生产用于医疗用途的热熔合成树脂构件的方法，其使得在将医疗用合成树脂构件热熔合的情况下，例如，可以将构成AVF针的相对软的热塑性管与另一种 部分比诸如针针的针座（毂）或具有比管更硬的配件连接器的部分（例如，血液回路，延长管，输液器等等）比管更硬 ），热塑性管构件的连接部分和比热塑性管构件更硬的另一构件可以快速且均匀地热熔融，并且可以在保持高生产率的同时自动连续地执行制造过程; 及其制造装置。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.035 秒)